To The Moon

$Eli Lilly(LLY)$ is scheduled to report its Q2 2025 earnings before the market opens on Thursday, August 7, 2025. Here is an analysis of what to expect and the key metrics for investors to monitor.

Revenue: Approximately $14.7 billion. This would represent a significant increase from the $11.3 billion reported in the same quarter last year.

Earnings Per Share (EPS): Around $5.61. This is a substantial jump from the $3.92 reported in Q2 2024.

Summary of Eli Lilly and Co (LLY) Fiscal Q1 2025 Earnings

Eli Lilly & Co. reported a robust Q1 2025, with revenue surging 45% year-over-year to $12.73 billion, primarily driven by the continued, explosive demand for its GLP-1 drugs, Mounjaro and Zepbound. The company's key products, including these two, contributed significantly to revenue growth. Non-GAAP earnings per share (EPS) were $3.34, a 29% increase from the prior year. Despite these strong results, the stock saw a negative reaction, largely due to a lowered full-year EPS guidance. The company reaffirmed its full-year revenue guidance of $58.0 billion to $61.0 billion, signaling confidence in top-line growth.

Lesson Learned from Guidance

The key lesson from Eli Lilly's Q1 2025 guidance is that for a high-growth company with a premium valuation, not all guidance is created equal. While the company reaffirmed its top-line revenue guidance, the stock's negative reaction was a direct result of the lowered EPS forecast. This reduction was not due to a fundamental weakness in the business, but rather to a significant one-time charge of $1.72 per share related to acquired in-process research and development (IPR&D) charges, stemming from a strategic acquisition.

This highlights a critical point for investors: the market is sensitive to every aspect of a company's guidance, and a change in one metric, even if it's a non-operational expense, can overshadow strong underlying performance. The lesson is that while revenue growth and product performance are crucial, investors must also closely scrutinize how strategic investments and one-time costs are impacting the bottom line and management's future projections.

Key Expectations and Drivers

Analysts are largely bullish on Eli Lilly's prospects, driven by the strong performance of its GLP-1 drugs for diabetes and weight loss, Mounjaro and Zepbound. The company's top-line growth is expected to be fueled by these products due to high demand, new international market launches, and improved supply from ramped-up production.

While growth is strong, some potential headwinds include pricing pressure and competition in the GLP-1 market. Sales of older drugs like Trulicity are also expected to be negatively impacted by competition and patients switching to newer GLP-1 treatments like Mounjaro.

Key Metrics to Watch For Fiscal Q2 Earnings

Investors should pay close attention to the following metrics and company commentary during the earnings call:

Sales of GLP-1 drugs: This is the most critical metric. Watch for specific sales figures for Mounjaro and Zepbound. Any indication of a slowdown in demand or supply chain issues could impact the stock. The combined revenue from these two drugs is expected to be a major driver of overall growth.

Guidance for the rest of 2025: Eli Lilly's updated full-year guidance for 2025 will be a key indicator of management's confidence in the company's growth trajectory. The company's ability to maintain or raise its outlook will be a major factor in investor sentiment.

Pipeline and R&D updates: Beyond the current blockbusters, investors will be listening for news on the company's pipeline, especially its oral GLP-1 drug, Orforglipron, and other new medicines in development. Updates on recent acquisitions and clinical trial results will also be important for long-term growth prospects.

Margins and Expenses: Higher marketing, selling, and administrative expenses to support new product launches may impact operating profits. Investors will want to see if the company can maintain healthy margins despite these investments.

Eli Lilly (LLY) Price Target

Based on 26 analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $968.78 with a high forecast of $1,190.00 and a low forecast of $675.00. The average price target represents a 26.48% change from the last price of $765.95.

Short-Term Trading Opportunities Post-Earnings

Trading Eli Lilly stock around an earnings announcement can be volatile. Historically, the stock has shown a mixed reaction to earnings reports. Over the past five years, the stock has had a negative one-day return following earnings in 56% of instances, with a median drop of -3.1%. However, it is worth noting that the stock has also experienced significant positive moves.

Here is what to consider for short-term trading opportunities:

Expect Volatility: The options market is currently pricing in a potential move of approximately +/- 6.15% following the earnings release. This suggests a significant price swing is anticipated, creating potential opportunities for option traders.

The "Surprise" Factor: The market has high expectations for Eli Lilly's Q2 performance. A significant earnings beat, especially from Mounjaro and Zepbound sales or a positive surprise in the company's guidance, could lead to a rally.

The "Disappointment" Factor: Conversely, any missed expectations—even if they are a beat on a year-over-year basis but a miss on analyst consensus—could trigger a sharp sell-off. A miss on sales, particularly from the key GLP-1 drugs, or a cautious outlook for the remainder of the year could be a negative catalyst.

Technical Analysis: As of recent reports, the stock has been trading below its 50-day and 200-day moving averages. A strong earnings report that pushes the stock back above these levels could signal a shift in momentum. Conversely, a poor report could accelerate the downward trend.

Technical Analysis - Exponential Moving Average (EMA)

Though analysts are expecting strong upcoming Q2 2025 earnings driven by high demand for its GLP-1 drugs, Mounjaro and Zepbound. But the negative momentum and the decline in the share price recently have shown that investors are still worried about the pharma tariffs impact on companies like LLY.

So there might still be a downward movement in share price even though earnings beat could be there, and investors are more concerned on how LLY is planning to navigate this tariffs impact scenario.

For traders, strategies could involve options to capitalize on the expected volatility. For instance, a long straddle or strangle could profit from a large move in either direction. Alternatively, a directional trade based on a well-researched opinion of the outcome could be used, though this carries a higher risk.

Given the historical tendency for negative one-day returns, a contrarian short-term play might be considered, but this should be weighed against the strong underlying fundamentals and long-term growth story.

Summary

Eli Lilly's upcoming Q2 2025 earnings are expected to be strong, driven by high demand for its GLP-1 drugs, Mounjaro and Zepbound. Analysts project revenue around $14.7 billion and EPS of $5.61.

Key metrics to watch include the sales of these blockbuster drugs, updated full-year guidance, and any updates on their clinical pipeline. The stock is expected to be volatile post-earnings, with the options market pricing in a potential swing of around 6%.

Strong results could lead to a rally, while any disappointment, especially concerning GLP-1 sales or guidance, could cause a sell-off.

Appreciate if you could share your thoughts in the comment section whether you think LLY would be able to produce a stellar figures for GLP-1 drugs, Mounjaro and Zepbound sales.

@TigerStars @Daily_Discussion @Tiger_Earnings @TigerWire appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.

Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.